Abstract
Objective To investigate the short-term efficacy and the influence of lyophilized recombinant human brain natriuretic peptide on ET-1 and CysC in patients with acute heart failure. Methods 126 cases of patients with acute heart failure in our hospital from January 2015 to May 2017 were chosen as experimental subjects, and were randomly divided into control group and research group, 63 cases in each group. The control group was treated with dobutamine, the research group was treated with lyophilized recombinant human brain natriuretic peptide. After treatment, clinical effect, the improvement of cardiac function, ET-1, CysC, Gal-3, and adverse reactions between the two groups were compared. Results The total effective rate of treatment in the research group was higher than that in the control group (90.48% vs.74.60%), with statistically significant difference (P 0.05). Conclusion Lyophilized recombinant human brain natriuretic peptide could effectively improve the expression levels of CysC, ET-1, and Gal-3, and promote the cardiac function, with good clinical effect and safety. Key words: Acute heart failure; Lyophilized recombinant human brain natriuretic peptide; Endothelin; Cystatin C; Cardiac function
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call